BACKGROUND: The authors evaluated a 3‐week schedule of bevacizumab in patients with
recurrent high‐grade glioma (HGG). METHODS: Patients received bevacizumab 15 mg/kg …

Objective: Bevacizumab has been shown to be effective in the treatment of recurrent
glioblastoma in combination with chemotherapy compared with historic controls but not in …

We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-
naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty …

BACKGROUND: The authors performed a phase 2 trial of combined protracted daily
temozolomide and biweekly bevacizumab for patients with recurrent glioblastoma who had …

Despite advances in upfront therapy, the prognosis in the great majority of patients with
glioblastoma (GBM) is poor as almost all recur and result in disease-related death …

Objective This single-arm, open-label, Phase II study evaluated the efficacy and safety of
single-agent bevacizumab, a monoclonal antibody against vascular endothelial growth …

BACKGROUND Bevacizumab received US Food and Drug Administration approval for use
in recurrent glioblastoma based on promising radiographic response data, but without clear …

Background Prognosis of unresectable glioblastoma (GB) remains poor, despite
temozolomide (TMZ)-based chemoradiation. Activity of bevacizumab (BEV) and irinotecan …

Object The presence of angiogenesis is a hallmark of glioblastoma (GBM). Vascular
endothelial growth factor (VEGF), which drives angiogenesis, provides an additional target …

The FDA's approval of bevacizumab for recurrent glioblastoma on May 9, 2009, was based
on the significant response rate and clinical benefits seen from randomized phase II studies …